News
Gabbard claimed on X that Obama had ordered the Intelligence Committee to produce an assessment that “they knew was false, ...
“They’ve realized that they can take a bit of a step further, that they can advance their policy priorities through those ...
Trump over the weekend requested that grand jury transcripts related to United States v. Epstein be unsealed—a seeming sop to ...
WuXi Biologics secures US FDA Pre-License Inspection approval for five facilities, first for commercial PFS line: Wuxi, China Wednesday, July 23, 2025, 13:00 Hrs [IST] WuXi Biolog ...
The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.
Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...
The FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license ...
The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (CT03767348) trial in advanced melanoma was not ...
Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...
Replimune Group Inc. shares sank to their lowest point ever after US regulators rejected a skin cancer treatment from the ...
Replimune shares collapsed on Tuesday after the U.S. Food and Drug Administration rejected the clinical-stage biotechnology company's proposed advanced melanoma treatment. Shares of the Woburn, Mass., ...
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results